NCT05824156 is a Phase 2 clinical trial of 5 mg/kg CM-101 in Nonalcoholic Steatohepatitis, sponsored by ChemomAb Ltd..

Who is sponsoring NCT05824156?

NCT05824156 is sponsored by ChemomAb Ltd..

What drugs are being tested in NCT05824156?

Interventions in NCT05824156: 5 mg/kg CM-101, Placebo.

What condition does NCT05824156 study?

NCT05824156 studies Nonalcoholic Steatohepatitis.

Is NCT05824156 still recruiting?

NCT05824156 is currently completed. Last updated 21 April 2023.

Last reviewed 2023-04-21 · How we verify

NCT05824156

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CM-101 in NASH Patients - The SPLASH Study

Completed Phase 2 Last updated 21 April 2023

What this trial tests

Phase 2 trial testing 5 mg/kg CM-101 in Nonalcoholic Steatohepatitis in 23 participants. Completed in 25 August 2022.

Timeline

24 February 2021

Primary endpoint
15 August 2022

25 August 2022

Quick facts

Lead sponsor	ChemomAb Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	23
Start date	24 February 2021
Primary completion	15 August 2022
Estimated completion	25 August 2022
Sites	9 locations across Israel

Drugs / interventions tested

5 mg/kg CM-101 — full drug profile →
Placebo

Conditions studied

Nonalcoholic Steatohepatitis — all drugs for Nonalcoholic Steatohepatitis →

Sponsor

ChemomAb Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Nonalcoholic Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 2a study is a multi-center, double-blind randomized, placebo-controlled study. The study is designed to determine the safety and tolerability of the anti-human CCL24 monoclonal antibody CM-101 in adult patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) patients with stage 1c, 2 or 3 fibrosis. The patients will be randomized to 1 of 2 treatment groups: 5 mg/kg CM-101 or placebo.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.
Schwabe RF, Tacke F, Sugimoto A, Friedman SL. · · 2025 · cited 13× · PMID 40689145 · DOI 10.1016/j.jhepr.2025.101421
The Intriguing Roles of Cytokines in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review.
Vachliotis ID, Polyzos SA. · · 2025 · cited 3× · PMID 40794228 · DOI 10.1007/s13679-025-00657-5
Targeting Hepatic Stellate Cells for the Prevention and Treatment of Liver Cirrhosis and Hepatocellular Carcinoma: Strategies and Clinical Translation.
Xiong H, Guo J. · · 2025 · cited 3× · PMID 40283943 · DOI 10.3390/ph18040507
CCL24 and Fibrosis: A Narrative Review of Existing Evidence and Mechanisms.
Greenman R, Weston CJ. · · 2025 · cited 3× · PMID 39851534 · DOI 10.3390/cells14020105

Verify or expand the search:

Other recruiting trials for Nonalcoholic Steatohepatitis

Currently open trials in the same condition.

NCT07481734 — Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) · Phase 2 · recruiting
NCT06465186 — A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) · Phase 2 · active not recruiting
NCT05526144 — Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans · Phase 2 · recruiting
NCT05330923 — Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease · recruiting
NCT04550481 — Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study · Phase 2 · active not recruiting

Other ChemomAb Ltd. trials

Trials by the same sponsor.

NCT06037577 — Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Hea · Phase 1 · completed
NCT06044467 — The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalc · Phase 1 · completed
NCT06025851 — Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Heal · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05824156 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ChemomAb Ltd.
Last refreshed: 21 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05824156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing